A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).

开始日期2021-08-17

申办/合作机构

Alkahest, Inc.

NCT04499235

/ Terminated临床2期

Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid

This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).

开始日期2020-01-30

申办/合作机构

Alkahest, Inc.

NCT04331730

/ Completed临床2期

A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration

This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).

开始日期2020-01-28

申办/合作机构

Alkahest, Inc.

100 项与 Lazucirnon 相关的临床结果

登录后查看更多信息

100 项与 Lazucirnon 相关的转化医学

登录后查看更多信息

100 项与 Lazucirnon 相关的专利（医药）

登录后查看更多信息

项与 Lazucirnon 相关的文献（医药）

2024-03-01·American journal of clinical dermatology

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Review

作者: Patsatsi, Aikaterini ; Karakioulaki, Meropi ; Eyerich, Kilian

ABASTRACT:

Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.

2022-06-01·RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES2区 · 医学

SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

2区 · 医学

Article

作者: Newman, Erin M. ; Sikorski, Bartosz L. ; Garg, Seema ; Stewart, Michael W. ; Rawner, Esther S. ; Jeffords, Elizabeth ; Konopińska, Joanna ; Jackson, Sam

Purpose::

To evaluate the safety and therapeutic effects of orally administered AKST4290 (formerly BI 144807 and ALK4290) in treatment-naive patients with neovascular age-related macular degeneration.

Methods::

In this prospective, multicenter, open-label Phase 2a pilot clinical study, 30 patients with newly diagnosed neovascular age-related macular degeneration self-administered AKST4290 (400 mg) orally twice daily for 6 weeks. Patients were examined weekly for safety, to measure best-corrected visual acuity (BCVA), and to perform exploratory morphologic assessments. The primary endpoint was the mean change in BCVA from baseline to end of treatment, and the secondary endpoint was safety. Exploratory endpoints investigated potential changes in macular morphology.

Results::

Mean BCVA improved by +7.0 letters (95% CI, 2.2–11.7); 24 patients (82.8%) had stable or improved BCVA, with 6 (20.7%) gaining ≥15 letters. No patients experienced severe or serious adverse events.

Conclusion::

In this 6-week study, AKST4290 treatment was associated with improved BCVA scores in patients with treatment-naive neovascular age-related macular degeneration. All adverse events were mild or moderate in severity and no safety issues were identified. Treatment of neovascular age-related macular degeneration with AKST4290 warrants further investigation in randomized, placebo-controlled trials.

2020-05-01·Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)4区 · 医学

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

4区 · 医学

ReviewOA

作者: Mahima Jhingan ; Anindya Samanta ; Aamir A. Aziz ; Jay Chhablani ; Arshad M. Khanani ; Sumit Randhir Singh

Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily 2 types-neovascular AMD (nAMD) with the presence of choroid neovascularization and nonneovascular AMD (nnAMD) with geographic atrophy. Although there are 4 anti-vascular endothelial growth factor drugs either widely used or approved for the former, there are no current treatments for the latter. This review will highlight upcoming treatments for AMD currently in clinical trials. For nAMD: Abicipar pegol, an intravitreal anti-vascular endothelial growth factor based on designed ankyrin repeat proteins (DARP) in protein, is currently pending approval. Conbercept and Faricimab, 2 intravitreal anti-growth factors, are currently in phase 3. Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.

项与 Lazucirnon 相关的新闻（医药）

2026-01-21

·今日头条

AI辅助药物研发：糖尿病视网膜病变口服疗法在路上

原创青白视角 Aggie 青白视角 2024年7月12日 14:15 浙江笔者曾在美国眼科创新热点：2015-2020专利趋势分析一文中结语写到：“另外，笔者也特别关注到，远程医疗和基于人工智能的诊断、药物发现等技术在美国专利趋势中并未得到突出反映，但众所周知，中国在数字技术领域的创新和产业化全球领先，同时中国未来人口结构的老龄化问题尤为凸显，因此这个领域或许是我们可以实现弯道超车的细分赛道之一......“ 本文提及的技术和案例正验证了笔者上述观点。前言对接（Docking）是一种用于药物发现的计算技术，用于预测小分子（候选药物）与目标蛋白质相互作用的“程度”。对接在药物发现的早期阶段至关重要，因为它能够高效筛选大量化合物库，节省时间和资源。近年来，基于人工智能的方法已成为分子对接的有前途的替代方案，具有高精度的潜力，而无需承担过高的计算成本。在全球范围内，分子对接市场是更广泛的药物发现信息学市场中的一个重要部分，预计该市场将从2023 年的30 亿美元增长到 2032 年的80 亿美元，这得益于制药公司对研发投资的增加和先进计算工具的采用。对接技术已从传统的基于物理/评分的方法发展到先进的基于深度学习/人工智能的方法。最初，对接依靠物理和化学原理来预测相互作用，使用评分函数根据几何和能量因素来评估结合亲和力。深度学习的出现使模型能够直接从数据中学习复杂的分子表征，从而改变了对接。这些深度学习模型可以捕捉以前难以建模的复杂模式和相互作用，从而实现更准确、更有效的预测。 AI在眼科药物研发中的应用基于人工智能的药物对接技术，在眼科疾病的药物研发中取得了显著进展。近日，国内深势科技（DP Technology ）宣布 DPT0415 被提名为治疗糖尿病视网膜病变 (DR) 和糖尿病黄斑水肿 (DME) 的临床前候选化合物。 2.1 Lp-PLA2 及其在DR和DME中的作用 DR 是糖尿病引起的微血管并发症，也是中老年人视力丧失的主要原因。1/3的糖尿病患者患有 DR。DME 可发生在 DR 的任何阶段，其原因是血视网膜屏障破裂导致黄斑中过多的液体和脂质积聚。抗VEGF药物的出现彻底改变了 DME 的治疗。然而，许多患者尽管尝试多次注射药物，仍未完全控制疾病，这可能是因为 DR 也是一种炎症性疾病，许多细胞因子和趋化因子参与了这一过程。因此，应探索 VEGF 以外的分子机制。 Lp-PLA2 属于 PLA2 超家族第 VII 组，主要由巨噬细胞分泌，与低密度脂蛋白 (LDL) 和高密度脂蛋白 (HDL) 形成复合物在血液中循环。Lp-PLA2 水解氧化磷脂，通常在低密度脂蛋白 (LDL) 上水解，生成溶血磷脂酰胆碱 (lysoPC)。LysoPC 会诱发血管炎症，导致血视网膜屏障 (BRB) 受损。 2015年葛兰素史克曾探索过作为 Lp-PLA2 抑制剂的达拉帕地（Darapladib）的口服疗法。在一项糖尿病性黄斑水肿 (DME) IIa 期研究中，研究结论显示：每日口服一次达拉帕地 3 个月可显著改善视力和黄斑水肿，值得进一步研究这种新型脂蛋白相关磷脂酶 A2 抑制机制在治疗 DME 方面的作用。 2.2 DPT0415 的临床前研究 DPT0415 是一种高效、选择性强且安全的 Lp-PLA2 抑制剂，具有新颖的结构。它在 0.3 mpk 时表现出足够的靶标参与度，并在 STZ 诱发的大鼠 DR 模型中控制了视网膜病变的进展。该化合物比达拉帕地具有更高的效力、更好的 ADME （药物吸收Absorption、分布Distribution、代谢Metabolism和外排Excretion的简称）和物理化学性质，并在临床前研究中展现出足够的安全性。目前，DME 的标准治疗方法是眼部注射 VEGF 抗体以保护视力。由于这种给药方式具有侵入性，患者往往会将治疗推迟到疾病的后期。作为治疗 DME 的口服疗法，DPT0415 可以通过靶向 Lp-PLA2 来治疗炎症和血管渗漏，从而改善视力。此外，Lp-PLA2 抑制剂 DPT0415 有可能通过在早期治疗 DME 来显著改变治疗模式，从而获得更好的疗效。 2.3 深势科技 2.3.1 技术平台、底层模型深势科技成立于2018年，总部位于北京，是 AI for Science 范式的领先企业，致力于整合“AI + 模拟 + 实验”来解决尚未满足的医疗需求。DPT0415 的成功发现得益于 RiDYMO® 平台中的 Uni-FEP 和 Uni-QSAR 等多个模块，以优化药效和 ADME 特性。该公司依托基于动态机制的药物设计平台RiDYMO®，建立了全球领先的药物发现平台，重点关注中枢神经系统、肿瘤和自身免疫性疾病三个领域。 RiDYMO®难成药靶标研发平台集成多种AI与物理算法，致力于针对“不可靶向”靶点和“最佳”分子进行药物开发。作为其核心算法之一的强化动力学（RiD）在分子动力学模拟的采样效率方面具有显著优势，充分利用神经网络的高维表征能力，高效捕捉复杂生物分子系统中的动态构象变化。为了推动人工智能在科学领域的应用，深势科技开源了其强大的基于人工智能的 Uni-Mol Docking v2 模型，并将其提供给科学界。Uni-Mol Docking v2 是一个在 AlphaFold3 之前发布的功能强大的对接模型。 Uni-Mol Docking v2 基于深势科技开发的预训练 AI 模型。Uni-Mol 在各种任务上取得了最先进的结果，表明其具有泛化能力，并使其成为分子任务的强大基础模型。Uni-Mol Docking v2 在 CASF-2016 基准测试中与传统对接算法（如 Autodock Vina）相比取得了卓越的性能。Uni-Mol Docking v2 在预测结合姿势方面具有更高的准确性，超过 77% 的配体的 RMSD 值低于 2.0 Å，超过 75% 的配体通过了所有质量检查。这标志着准确率从 62% 大幅提升，也超越了其他已知的开源方法深势科技的业务版图不仅仅在医药领域，其依托在交叉学科领域深耕，构建了“深势·宇知®”AI for Science大模型体系，将众多学科的科研方法从“实验试错/计算机”时代带入了“预训练模型时代”，机器“微观尺度工业设计与仿真”为切入点，除打造了Hermite®药物计算设计平台、RiDYMO®难成药靶标研发平台外，也构建了Bohrium®玻尔科研空间站及Piloteye®电池设计自动化平台等科研和工业研发基础设施，形成了AI for Science的“创新-落地”链路和开放生态，赋能“千行百业”，为生物医药、能源、材料和信息科学与工程研究打造新一代工业设计与仿真系统。 2.3.2 融资情况数据源：药融云，制表：青白视角结语通过将人工智能与分子对接技术相结合，DPT0415 的成功发现展示了人工智能在药物发现中的巨大潜力，推动了眼科领域的药物研发。未来，期待国内更多深势科技出现，通过开放科学和协作来加速发现，并在全球范围内推动各个领域的有意义的进步。补充：创新口服视网膜疗法热度有增无减「1」以下简单罗列几种创新口服视网膜疗法（有数十种）。适应证方向主要在糖尿病视网膜病变、黄斑变性和斯塔加特病等视网膜疾病。 3.1 AKST4290(Alkahest) AKST4290是一种每日两次口服的趋化因子 CC 基序受体 3 (CCR3) 抑制剂，嗜酸细胞趋化因子是一种免疫调节蛋白，随着人类年龄的增长导致特定的年龄相关疾病。AKST4290可减少新诊断、未接受治疗的湿性AMD的标志性炎症和新生血管形成。 3.2 ALK-001（阿尔克斯制药） ALK-001 是维生素 A 的口服改良形式，旨在减缓有毒维生素 A 聚集体或“二聚体”的形成，而有毒维生素 A 聚集体或“二聚体”会导致这些疾病。ALK-001 用于治疗继发于干性 AMD 的GA 和Stargardt 病。 3.3 LBS-008（Belite Bio ） LBS-008 为一种针对干性 AMD 的一流口服小分子血清视黄醇结合蛋白 4 (RBP4) 特异性拮抗剂。LBS-008 减少循环系统维生素 A 的水平，从而减少向眼睛递送，适应证为干性 AMD 和 Stargardt 病。 3.4 Xiflam（OcuNexus） Xiflam 是一种口服小分子药物，一种连接蛋白半通道阻滞剂，可阻断连接蛋白 43 (Cx43) 半通道，该半通道已被证明在渗出性视网膜疾病中过度表达。该化合物于 20 年前开发用于偏头痛治疗后因公司合并而停止了开发。现在适应证为DME、湿性 AMD 和 GA。 3.5 OCX063 (Occurx) OCX063 一种口服抗炎抗纤维化药物，用于治疗增殖性玻璃体视网膜病变、nAMD 和非增殖性糖尿病视网膜病变 (NPDR)。 3.6 RZ402（Rezolute Bio） RZ402 是一种每日一次的口服疗法，针对激肽释放酶-激肽系统，抑制血浆激肽释放酶，从而阻断下游缓激肽的产生以及导致 DME 的并发症。 3.7 酪氨酸激酶抑制剂X-82 (Tyrogenex) 一种口服酪氨酸激酶抑制剂，对VEGF 受体 (VEGFR) 和血小板衍生生长因子受体 (PDGFR) 有活性，眼部适应证为 nAMD。 3.8 danegaptide（Breye）通过靶向细胞间的间隙连接来维持血管结构的完整性，防止由高葡萄糖应激条件引起的细胞间解偶联、视网膜毛细血管破裂和血管渗漏。这药物已经在用于治疗心肌梗塞的临床试验中表现出良好的安全性。眼部适应证为DR、DME、AMD 。参考 1、青白视角|又一口服视网膜疗法启动临床：一直在路上

2023-04-20

·PRNewswire

Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight

Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important dopamine chemical. Studies have shown that symptoms of Parkinson's develop in patients with an 80% or greater loss of dopamine-producing cells in the substantia nigra. Most Parkinson's patients are treated with medications to relieve the symptoms of the disease. These medications work by stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or by inhibiting some of the acetylcholine that is produced (anticholinergic medications), therefore restoring the balance between the chemicals in the brain. LAS VEGAS, April 19, 2023 /PRNewswire/ -- DelveInsight's ' Parkinson's Disease Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline Parkinson's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Parkinson's disease pipeline domain. Key Takeaways from the Parkinson's Disease Pipeline Report DelveInsight's Parkinson's disease pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies for Parkinson's disease treatment. Key Parkinson's disease companies such as Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others are evaluating new Parkinson's disease drugs to improve the treatment landscape. Promising Parkinson's disease pipeline therapies in various stages of development include Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, Aadipose-Derived Mesenchymal Stem Cells, ND0612, P2B001, 1ST-103, 1ST-105, and others. In January 2023, Neurocrine Biosciences and Voyager Therapeutics announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases. The collaboration includes Voyager's preclinical, intravenously administered GBA1 gene therapy program for Parkinson's and other GBA1-mediated diseases, combining a GBA1 gene replacement payload with novel capsids from Voyager's TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform. In addition, Neurocrine Biosciences and Voyager have agreed to collaborate on three new gene therapy programs directed to rare CNS targets, each also leveraging Voyager's novel TRACER capsids. In October 2022, Biogen Inc. and Denali Therapeutics Inc. announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 (DNL151), as compared to placebo in approximately 400 participants with Parkinson's disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene. In September 2022, Neuron23, Inc. an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. Request a sample and discover the recent advances in Parkinson's disease drug treatment @ Parkinson's Disease Pipeline Report The Parkinson's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Parkinson's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Parkinson's disease clinical trial landscape. Parkinson's Disease Overview Parkinson's disease is a progressive disorder caused by nerve cell degeneration in the substantia nigra, a part of the brain that controls movement. These nerve cells die or become impaired, losing the ability to produce dopamine, an important chemical. According to research, symptoms of Parkinson's disease develop in patients who have an 80% or greater loss of dopamine-producing cells in the substantia nigra. Dopamine works typically in tandem with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in the movement. This balance is disrupted when there is insufficient dopamine, resulting in tremors (trembling in the hands, arms, legs, and jaw), rigidity (stiffness of the limbs), slowness of movement, and impaired balance and coordination - the hallmark Parkinson's disease symptoms. The cause of Parkinson's disease is largely unknown. However, as potential causes of the disease, theories involving oxidative damage, environmental toxins, genetic factors, and accelerated aging have been discussed. The majority of Parkinson's patients are given medications to alleviate their symptoms. These Parkinson's disease medications work by either stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or inhibiting some of the acetylcholine produced (anticholinergic medications), restoring the balance of chemicals in the brain. Find out more about drugs for Parkinson's disease @ New Parkinson's Disease Drugs A snapshot of the Parkinson's Disease Pipeline Drugs mentioned in the report: Learn more about the emerging Parkinson's disease pipeline therapies @ Parkinson's Disease Clinical Trials Parkinson's Disease Therapeutics Assessment The Parkinson's disease pipeline report proffers an integral view of Parkinson's disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Parkinson's Disease Pipeline Report Coverage: Global Parkinson's Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Parkinson's Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Parkinson's Disease Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous Parkinson's Disease Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine Parkinson's Disease Therapeutics Assessment By Mechanism of Action: Dopamine D1 receptor agonists, Dopamine D5 receptor agonists, Bcr-abl tyrosine kinase inhibitors, Glucagon like peptide 1 receptor agonists, LRRK2 protein inhibitors, Alpha-synuclein inhibitors, Dopamine receptor agonists Key Parkinson's Disease Companies: Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others. Key Parkinson's Disease Pipeline Therapies: Tavapadon, IkT-148009, NLY01, PT320, BIIB122, Prasinezumab, KDT-3594, AAV2-GDN, AKST4290, anle138b, ITI-214, NTCELL, Buntanetap, ANAVEX2-73, ATH-1017, NE3107, MEDI1341, AZD0328, Liraglutide, UB-312, LY03003, FB-101, AV-101, ABBV-951, NYX-458, DSP-9632P, Valiloxybate, SER-214, UCB7853, TAK-071, XC130-A10H, K0706, Talineuren, Pirepemat, Lu AF28996, WD-1603, CVN424, CST-103, NBTX-001, MSK-DA01, Aadipose-Derived Mesenchymal Stem Cells, ND0612, P2B001, and others. Dive deep into rich insights for new drugs for Parkinson's disease treatment; visit @ Parkinson's Disease Medications Table of Contents For further information on the Parkinson's disease pipeline therapeutics, reach out @ Parkinson's Disease Drug Treatment Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, among others. Parkinson's Disease Epidemiology Forecast Parkinson's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Parkinson's disease epidemiology trends. Dementia with Lewy Bodies Pipeline Dementia with Lewy Bodies Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dementia with Lewy bodies companies, including Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others. Dementia with Lewy Bodies Epidemiology Forecast Dementia with Lewy Bodies Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted dementia with Lewy bodies epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Dementia Market Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies, including Hoffmann-La Roche, Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis, among others. Parkinson's Disease-Related Dementia Market Parkinson's Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床3期

2022-06-13

·PRNewswire

The Age-related macular degeneration market growth is expected to boost owing to the expected launch of therapies, increasing prevalence of Age-related macular degeneration, development in the field of gene therapy, patient-friendly dosage regimes, and several other factors during the forecast period. LAS VEGAS, June 13, 2022 /PRNewswire/ -- DelveInsight's Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, Age-related macular degeneration emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key Takeaways from the Age-related Macular Degeneration Market Report As per DelveInsight analysis, the Age-related macular degeneration market size in the 7MM was approximately USD 9.8 billion in 2021. As per DelveInsight estimation, the Dry AMD market size was approximately USD 1,377 million, and the Wet AMD market size was approximately USD 8,463 million, which is further expected to increase by 2032. As per the estimates, the total Age-related macular degeneration prevalent cases in the 7MM was approximately 51.7 million in 2021. Leading Age-related macular degeneration companies Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others are developing novel Age-related Macular Degeneration drugs which can be available in the Age-related Macular Degeneration market in the upcoming years. The Wet Age-related macular degeneration therapies in the pipeline include OPT-302, KSI-301, RGX-314, AKST4290, GB-102 (Sunitinib Malate), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), and others. The Dry Age-related Macular Degeneration therapies in the pipeline include Danicopan (ALXN2040), EG-301, RG6147 (RO7171009), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others. The expected launch of therapies and the increasing prevalence will lead to Age-related macular degeneration market growth during the forecast period. Discover more about therapies set to grab major age-related macular Degeneration market share @ Age-related Macular Degeneration Market Landscape Age-related Macular Degeneration Overview Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries around the world, with a significant impact on the quality of life of the affected people. With the current expensive standard of care, the increase in Age-related macular degeneration life expectancy brings an increase in the number of reported cases, putting major stress on health care systems. Age-related macular degeneration (AMD) can also be characterized as either dry Age-related macular degeneration (atrophic or non-neovascular) or wet Age-related macular degeneration (exudative or neovascular). The most common Age-related macular degeneration symptoms include blurry or fuzzy vision, loss of central vision, difficulty in recognizing familiar faces, and others. Visual acuity test, pupil dilation, fluorescein angiography, Amsler grid, and others are the following tests used for Age-related macular degeneration diagnosis. Age-related Macular Degeneration Epidemiology Segmentation As per DelveInsight, there were approx 51.7 million Age-related macular degeneration prevalent cases in the 7MM in 2021. Among the total diagnosed cases of Age-related macular degeneration, the highest cases were observed for dry Age-related macular degeneration in 2021. The Age-related macular degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases of Age-related Macular Degeneration Total Diagnosed Prevalent Cases of Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases of AMD Total Age-specific Cases of Wet AMD, and Dry AMD Total Diagnosed Dry AMD Cases by Stages Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment Download the report to understand which factors are driving Age-related macular degeneration epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights Wet Age-related Macular Degeneration Treatment Market Photodynamic therapy, which employed an intravenous drug (injected into a vein) and laser to seal off bleeding blood vessels, was the best available Age-related macular degeneration treatment fifteen years ago. However, improvements in medical research have revealed VEGF as a critical pathophysiological factor in the development of neovascular AMD, with an important involvement in angiogenesis, vascular permeability, and inflammatory response. Anti-VEGF intravitreal injections have provided a new therapeutic window in the wet AMD treatment, effectively stopping the pathophysiological process of AMD and restoring retinal shape and function. Anti-VEGF therapies such as ranibizumab, aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo) are intravitreal injections given for wet AMD treatment. Though existing anti-VEGF therapies have transformed the way wet AMD is treated and greatly improved the lives of many patients, they will face stiff competition from new biosimilars and off-label drugs when their patents expire in the coming years. Furthermore, current anti-VEGF therapies have several unmet needs. Dry Age-related Macular Degeneration Treatment Market Currently, there is no approved dry AMD treatment, and there is a significant unmet need for a therapy to decrease its progression. Dry AMD's pathogenesis is poorly known. On the other hand, failure to achieve the primary outcomes may be due to the advanced stage of the disease rather than a lack of action on appropriate targets. Several pharmaceutical companies are currently working on developing novel therapies for dry AMD treatment. The therapies in the dry AMD pipeline include Pegcetacoplan (Apellis Pharmaceuticals), Zimura (Iveric bio), RO7171009; RG6147 (Genentech), IONIS-FB-LRx (Ionis Pharmaceuticals/ Roche), Luminate (Allegro Ophthalmics), NGM621 (NGM Biopharmaceuticals), Elamipretide (Stealth BioTherapeutics), CPCB-RPE1 (Regenerative Patch Technologies), OpRegen (CellCure Neurosciences/Lineage Cell Therapeutics/ Roche), GT005 (Gyroscope Therapeutics), and others. These therapies come with different types of mechanisms of action, including C3 inhibitor, C5 inhibitor, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitor, HtrA1, ASO Complement Factor B, and others. Two C3 inhibitors, NGM621 (NGM Biopharmaceuticals) and pegcetacoplan (Apellis Pharmaceuticals), and one C5 inhibitor, Zimura (Iveric Bio), are showing promise as prospective treatments to slow the course of geographic atrophy. To know more about Age-related macular degeneration treatment visit @ Age-related Macular Degeneration Treatment Guidelines Wet Age-related Macular Degeneration Pipeline Therapies and Key Companies OPT-302: Opthea Limited KSI-301: Kodiak Sciences Inc. RGX-314: REGENXBIO AKST4290: Alkahest Inc GB-102 (Sunitinib Malate): Graybug Vision RBM-007: Ribomic USA Inc Lytenava (Bevacizumab-vikg): Outlook Therapeutics, Inc. UBX1325: Unity Biotechnology, Inc PAN-90806: PanOptica, Inc. CLS-AX (Axitinib): Clearside Biomedical Others Dry Age-related Macular Degeneration Pipeline Therapies and Key Companies Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca EG-301: Evergreen Therapeutics RG6147 (RO7171009): Roche (Genentech) ALK-001: Alkeus Pharmaceuticals Elamipretide: Stealth BioTherapeutics OpRegen: CellCure Neurosciences CPCB-RPE1: Regenerative Patch Technologies Luminate (Risuteganib): Allegro Ophthalmics ANX007: Annexon Biosciences NGM621: NGM Biopharmaceuticals LNP023 (Iptacopan): Novartis IONIS-FB-LRx: Ionis Pharmaceuticals Pegcetacoplan: Apellis Pharmaceuticals Zimura (Avacincaptad Pegol): Iveric Bio GT005: Gyroscope Therapeutics and Novartis RPESC-RPE-4W: Luxa Biotechnology GEM103: Gemini Therapeutics Others Learn more about the dry AMD treatments in clinical trials @ New Treatment for Dry AMD Wet Age-related Macular Degeneration Market Dynamics The rising prevalence of wet AMD and the growing geriatric population are two significant factors driving the growth of the wet AMD market. Moreover, the wet AMD market dynamics are changing as extensive research and development have helped understand the histopathology and pathophysiology of wet AMD. Development in the field of gene therapy and a robust pipeline are also propelling the wet AMD market growth. However, some factors restrain the growth of the wet AMD market. Patients do not contact a physician until they have intermediate to severe AMD symptoms, making timely diagnosis extremely difficult. Moreover, the high cost of therapy, with gene therapy costing over USD 400,000, presents a significant barrier to treatment availability. In addition, the competitive treatment landscape and emerging biosimilars may also limit the growth of the wet AMD market. Dry Age-related Macular Degeneration Market Dynamics The dry AMD market is still untapped. The enormous and growing patient pool with no approved or adequate therapies provides companies with attractive prospects; the estimated potential is similar to wet AMD. Moreover, the dry AMD pipeline includes peptide derivatives, antibodies, antisense oligonucleotides, stem cell treatment, and gene therapy that function on various mechanisms such as C1q, C3, and C5 inhibitors, cell replacements, HtrA Serine Peptidase 1 inhibitor, and others. The launch of these therapies will boost the dry AMD market growth. Furthermore, the increasing prevalence of dry AMD is also driving the dry AMD market forward. However, limited knowledge of pathophysiology, disease severity, and consequences affect the development of efficacious treatment for dry AMD. Moreover, emerging gene therapies and stem cell therapies for dry AMD may face hurdles in access and reimbursement due to their anticipated high cost and will restrain the growth of the dry AMD market. Scope of the Age-related Macular Degeneration Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Age-related Macular Degeneration Companies: Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others Key Wet Age-related Macular Degeneration Therapies: OPT-302, KSI-301, RGX-314, AKST4290, GB-102 (Sunitinib Malate), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), and others Key Dry Age-related Macular Degeneration Therapies: Danicopan (ALXN2040), EG-301, RG6147 (RO7171009), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others Therapeutic Assessment: Age-related Macular Degeneration current marketed and emerging therapies Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement Discover more about Age-related macular degeneration drugs in development @ Age-related Macular Degeneration Clinical Trials Table of Contents Get in touch with our Business executive @ Healthcare Due Diligence Services Related Reports Age-related Macular Degeneration Epidemiology Age-related Macular Degeneration Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Age-related Macular Degeneration epidemiology in the 7MM. Age-related Macular Degeneration Pipeline Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Age-related Macular Degeneration companies including Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc. , among others. Wet Age-related Macular Degeneration Market Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wet Age-related Macular Degeneration companies including Alkahest Inc, Graybug Vision, Clearside Biomedical, among others. Dry Age-related Macular Degeneration Market Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Dry Age-related Macular Degeneration companies including Alkeus Pharmaceuticals, Dobecure, Iveric Bio, among others. Wet Age-related Macular Degeneration Pipeline Wet Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wet Age-related Macular Degeneration companies including Opthea Limited, Kodiak Sciences Inc., REGENXBIO, among others. Dry Age-related Macular Degeneration Pipeline Dry Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dry Age-related Macular Degeneration companies including Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, among others. Other Trending Reports Periodontal Disease Market | Open-Angle Glaucoma Market | Obsessive-Compulsive Disorder Market | Nicotine Addiction Market | Nephrosclerosis Market | Muscle Invasive Bladder cancer Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market Related Healthcare Blogs Dry AMD Market: Pegcetacoplan vs Zimura Wet Age-related Macular Degeneration Market Outlook Eye Disorders Treatment Market About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

基因疗法抗体生物类似药寡核苷酸细胞疗法

100 项与 Lazucirnon 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15269

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非增殖性糖尿病视网膜病变	临床2期	美国	Alkahest, Inc.	2021-08-17
大疱性类天疱疮	临床2期	德国	Alkahest, Inc.	2020-01-30
帕金森病	临床2期	美国	Alkahest, Inc.	2020-01-16
帕金森病	临床2期	爱沙尼亚	Alkahest, Inc.	2020-01-16
帕金森病	临床2期	德国	Alkahest, Inc.	2020-01-16
帕金森病	临床2期	波兰	Alkahest, Inc.	2020-01-16
帕金森病	临床2期	斯洛伐克	Alkahest, Inc.	2020-01-16
湿性年龄相关性黄斑变性	临床2期	匈牙利	Alkahest, Inc.	2018-04-04
湿性黄斑变性	临床2期	匈牙利	Alkahest, Inc.	2017-01-18
炎症	临床1期	美国	Alkahest, Inc.	2018-09-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05038020 (CTgov)	临床2期	非增殖性糖尿病视网膜病变 \| 糖尿病性视网膜病变	3	AKST4290 (AKST4290)	艱鬱齋顧憲築積鑰憲糧(衊鹽夢艱願淵膚製夢網) = 襯網憲窪構壓觸糧艱選遞壓襯衊鬱衊簾顧壓衊 (鏇襯膚窪醖鬱艱積廠艱, 範繭夢夢觸鹹醖獵簾構 ~ 淵餘糧襯鏇願簾憲蓋蓋) 更多	-	2023-11-01
				Placebo (Placebo)	艱鬱齋顧憲築積鑰憲糧(衊鹽夢艱願淵膚製夢網) = 選膚襯築鹽醖鹹遞憲鏇遞壓襯衊鬱衊簾顧壓衊 (鏇襯膚窪醖鬱艱積廠艱, 餘壓艱積艱壓襯願製廠 ~ 鹽製鏇膚襯鬱網蓋艱鬱) 更多
NCT04499235 (CTgov)	临床2期	大疱性类天疱疮	6	Mometasone furoate+AKST4290 (Mometasone Furoate + AKST4290)	醖遞齋範窪夢顧築觸積 = 窪構壓選蓋窪積簾範鏇鬱夢廠醖鏇淵艱範廠醖 (繭鏇淵蓋觸觸觸觸膚鬱, 鹽艱繭廠繭齋選餘糧顧 ~ 衊鏇糧鏇鏇糧襯鬱衊壓) 更多	-	2023-09-14
				Placebo+Mometasone furoate (Mometasone Furoate + Placebo)	醖遞齋範窪夢顧築觸積 = 襯鏇鏇鹽願築窪糧鑰壓鬱夢廠醖鏇淵艱範廠醖 (繭鏇淵蓋觸觸觸觸膚鬱, 衊壓膚鏇醖蓋窪齋繭鬱 ~ 窪選選壓獵簾窪構憲窪) 更多
NCT04331730 (PHTHALO-205, CTgov)	临床2期	湿性年龄相关性黄斑变性	107	Aflibercept+AKST4290 (AKST4290 (800 mg) + Aflibercept)	憲鏇顧餘糧窪鹽餘鏇鑰(簾獵壓網衊築壓壓積顧) = 網獵鹹構觸艱齋鹽網繭遞衊壓壓膚壓網艱觸糧 (夢膚範觸壓鬱範鏇襯範, 10.26) 更多	-	2022-10-26
				Aflibercept+AKST4290 (AKST4290 (1600 mg) + Aflibercept)	憲鏇顧餘糧窪鹽餘鏇鑰(簾獵壓網衊築壓壓積顧) = 鬱襯膚淵餘鹽窪鹹蓋製遞衊壓壓膚壓網艱觸糧 (夢膚範觸壓鬱範鏇襯範, 7.89) 更多
NCT04369430 (TEAL, CTgov)	临床2期	帕金森病	110	AKST4290 (AKST4290)	膚淵範範繭膚壓網憲鏇(構繭願遞蓋醖窪艱鹽鹽) = 憲簾壓選艱鬱鏇積獵鹽構構憲簾積遞簾襯憲範 (夢構窪製築鑰廠遞蓋壓, 1.1844) 更多	-	2022-10-10
				Placebo (Placebo)	膚淵範範繭膚壓網憲鏇(構繭願遞蓋醖窪艱鹽鹽) = 顧壓簾鹹廠鹽構廠壓繭構構憲簾積遞簾襯憲範 (夢構窪製築鑰廠遞蓋壓, 1.1839) 更多
NCT03558074 (CTgov)	临床2期	湿性年龄相关性黄斑变性	26	ALK4290	鏇窪簾淵壓衊淵窪簾糧(鹹糧壓壓網醖窪願淵製) = 蓋觸選蓋獵選觸衊醖獵蓋範遞餘築願觸鑰齋糧 (繭窪醖鏇製繭壓廠襯蓋, 6.96) 更多	-	2020-08-28
NCT03558061 (CTgov)	临床2期	湿性年龄相关性黄斑变性	30	ALK4290	壓夢蓋鹹網壓艱衊積顧(艱齋夢築廠蓋簾艱膚壓) = 艱廠壓鹽製憲鹹餘顧糧窪築鏇獵遞簾製顧願構 (製襯蓋獵齋廠淵鏇鏇觸, 12.51) 更多	-	2020-08-28
NCT03558074 (GlobeNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	26	AKST-4290	蓋糧網憲鏇簾壓襯製糧(廠鬱膚壓觸蓋簾醖糧壓) = 鏇鹽窪齋艱鏇積網範顧鹽範鏇鑰鏇鹽壓憲蓋鹽 (製顧夢構襯襯醖壓膚範 ) 更多	积极	2019-07-29